Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.

导出 OA

翻译打印收藏纠错

作者： Cornelia,Kolberg-Liedtke ^[1] ; Oleg,Gluz ^[2] ; Fred,Heinisch ^[3] ; Friedrich,Feuerhake ^[4] ; Hans,Kreipe ^[5] ; Michael,Clemens ^[5] ; Benno,Nuding ^[6] ; Wolfram,Malter ^[7] ; Toralf,Reimer ^[8] ; Rachel,Wuerstlein ^[9] ; Monika,Graeser ^[2] ; Steve,Shak ^[10] ; Ulrike,Nitz ^[2] ; Ronald,Kates ^[3] ; Matthias,Christgen ^[10] ; Nadia,Harbeck ^[2]

作者单位： Gynäkologie mit Brustzentrum, Charité-Universitätsmedizin Berlin, Berlin, Germany. cornelia.kolberg-liedtke@charite.de. ^[1] West German Study Group, Mönchengladbach, Germany. ^[2] Ev. Hospital Bethesda, Breast Center Niederrhein, Moenchengladbach, Germany. ^[3] Institute of Pathology, Medical School Hannover, Hannover, Germany. ^[4] Department of Oncology, Clinics Mutterhaus der Borromaeerinnen, Trier, Germany. ^[5] Department of Gynecology and Obstetrics, Evangelical Hospital, Bergisch Gladbach, Germany. ^[6] Department of Gynaecology and Obstertrics, Faculty of Medicine and University Hospital Cologne, Cologne, Germany. ^[7] Department of Gynaecology and Obstetrics, University Clinics Rostock, Rostock, Germany. ^[8] Breast Center, Department of Gynecology and Obstetrics, University of Munich (LMU) and CCCLMU, Munich, Germany. ^[9] Genomic Health, Inc., Redwood City, CA, USA. ^[10]

关键词 Adjuvant chemotherapy Breast cancer Disease-free survival Hormone receptor status Tumor-infiltrating lymphocytes (TILs)